Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Epstein-Barr Virus Infection
Infectious Mononucleosis
Herpesvirus

Interventions

DRUG: Matrix-M1 Adjuvant
DRUG: EBV gp350-Ferritin Vaccine
OTHER: Placebo Comparator

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)